Adamas Pharmaceuticals, Inc.
NASDAQ Global MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Adamas Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders in the United States. Its core products include GOCOVRI, an extended-release capsule for treating dyskinesia in Parkinson's disease patients receiving levodopa-based therapy, and OSMOLEX ER, an extended-release tablet for Parkinson’s disease and drug-induced extrapyramidal reactions in adults. The company also offers NAMZARIC and NAMENDA XR, combination and extended-release capsules used to treat moderate to severe Alzheimer's disease dementia. Additionally, Adamas is developing ADS-4101, an extended-release formulation for partial onset seizures in epilepsy patients. Founded in 1997 and headquartered in Emeryville, California, Adamas operates primarily in the CNS (central nervous system) therapeutic segment targeting neurologic and neurodegenerative disorders. A major recent change for Adamas Pharmaceuticals is its acquisition by Supernus Pharmaceuticals in October 2021 for approximately $450 million, which strengthened Supernus’ CNS product portfolio with Adamas’ marketed products GOCOVRI and OSMOLEX ER. Since the acquisition, Adamas' strategic focus has centered on leveraging these therapies in neurology, with particular emphasis on Parkinson’s disease treatment. The company completed the acquisition of OSMOLEX ER and amended related royalty-backed loan agreements to support its growth strategy. These operational changes signal a strategic expansion under Supernus’ ownership aimed at driving near-term accretion from its key product offerings while continuing development of novel therapies like ADS-4101. Adamas Pharmaceutical's brand and product portfolio now function as an integral part of Supernus Pharmaceuticals' broader CNS franchise.
Time Sensitive - Reminder from Levi & Korsinsky, LLP to File Claim for Share of Adamas Pharmaceuticals, Inc. (ADMS) Settlement Fund Before Deadline
$4,650,000 Recovery from Adamas Pharmaceuticals, Inc. (ADMS). L&K, LLP Reminds Shareholders to File a Claim Before Deadline
Deadline Approaching for Receiving Share of Adamas Pharmaceuticals, Inc. (ADMS) Recovery - Contact Levi & Korsinsky, LLP for Further Details
Deadline Approaching for Receiving Share of Adamas Pharmaceuticals, Inc. (ADMS) Recovery - Contact Levi & Korsinsky, LLP for Further Details
Levi & Korsinsky, LLP Announces $4,650,000 Recovery for Adamas Pharmaceuticals, Inc. (ADMS). File Your Claim Before Deadline
Looming Deadline - Levi & Korsinsky Encourages Shareholders of Adamas Pharmaceuticals, Inc. (ADMS) to File a Share in Class Action Recovery
Looming Deadline - Levi & Korsinsky Encourages Shareholders of Adamas Pharmaceuticals, Inc. (ADMS) to File a Share in Class Action Recovery
Levi & Korsinsky, LLP Notifies Shareholders of Adamas Pharmaceuticals, Inc. (ADMS) an Upcoming Claims Deadline in a Class Action Settlement
Levi & Korsinsky, LLP Notifies Shareholders of Adamas Pharmaceuticals, Inc. (ADMS) an Upcoming Claims Deadline in a Class Action Settlement
Levi & Korsinsky, LLP Notifies Shareholders of Adamas Pharmaceuticals, Inc. (ADMS) an Upcoming Claims Deadline in a Class Action Settlement
Glancy Prongay & Murray LLP Announces the Proposed Class Action Settlement on Behalf of Purchasers of the Publicly Traded Common Stock of Adamas Pharmaceuticals, Inc. - ADMS
Lab-grown diamond maker Adamas One raises $11 mln in IPO
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates FTSI, UMPQ, FLXN, ADMS; Shareholders are Encouraged to Contact the Firm
SHAREHOLDER ALERT: WeissLaw LLP Reminds ADMS, FLXN, AZPN, and EBMT Shareholders About Its Ongoing Investigations
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Adamas Pharmaceuticals, Inc. - ADMS
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into the Fairness of the Merger of Adamas Pharmaceuticals, Inc. with Supernus Pharmaceuticals, Inc.
Shareholder Alert: Ademi LLP investigates whether Adamas Pharmaceuticals, Inc. has obtained a Fair Price in its transaction with Supernus
ADMS Stock Soars 70% Thanks to Adamas Pharmaceuticals Acquisition News
Adamas Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Adamas Pharmaceuticals, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – ADMS
Supernus Bolsters Parkinson's Portfolio With $450M Adamas Buyout: Highlights